---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-25-000043"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:04:40.628230+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience Q1 net loss $11.1M; nimacimab combo shows >30% weight loss in preclinical

## Summary
- Net loss for Q1 2025 was $11.1M ($2.2M non-cash share-based comp) vs $5.0M in Q1 2024.
- Cash and short-term investments total $59.2M; expected to fund operations through at least Q1 2027.
- Preclinical DIO model: nimacimab + tirzepatide achieved >30% weight loss; nimacimab alone 23.5% comparable to monlunabant and tirzepatide alone.
- In vitro data shows superior potency of peripherally restricted nimacimab vs small molecule monlunabant under pathological CB1 agonist levels.
- Top-line data from Phase 2a CBeyond study of nimacimab expected late Q3/early Q4 2025.

## SEC filing metadata
- accession: 0001516551-25-000043
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/0001516551-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-25-000043
- JSON: https://secwatch.observer/filing/0001516551-25-000043.json
- Plain text: https://secwatch.observer/filing/0001516551-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.